Peer-influenced content. Sources you trust. No registration required. This is HCN.

First-Line NALIRIFOX Shows Promising Antitumor Activity in Locally Advanced/Metastatic PDAC

In this podcast from the virtual 2020 ESMO World Congress on Gastrointestinal Cancer, Dr. Zev Wainberg discusses emerging data from the phase 1/2 trial of first-line liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin for pancreatic ductal adenocarcinoma (PDAC).

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form